AU2003220855A1 - Medicinal antitumor composition - Google Patents

Medicinal antitumor composition

Info

Publication number
AU2003220855A1
AU2003220855A1 AU2003220855A AU2003220855A AU2003220855A1 AU 2003220855 A1 AU2003220855 A1 AU 2003220855A1 AU 2003220855 A AU2003220855 A AU 2003220855A AU 2003220855 A AU2003220855 A AU 2003220855A AU 2003220855 A1 AU2003220855 A1 AU 2003220855A1
Authority
AU
Australia
Prior art keywords
medicinal
antitumor composition
antitumor
composition
medicinal antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003220855A
Inventor
Shinichi Kurakata
Tomoyuki Shibata
Naomi Shimazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of AU2003220855A1 publication Critical patent/AU2003220855A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2003220855A 2002-04-01 2003-03-27 Medicinal antitumor composition Abandoned AU2003220855A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002098128 2002-04-01
JP2002-98128 2002-04-01
JP2002-184361 2002-06-25
JP2002184361 2002-06-25
PCT/JP2003/003881 WO2003082865A1 (en) 2002-04-01 2003-03-27 Medicinal antitumor composition

Publications (1)

Publication Number Publication Date
AU2003220855A1 true AU2003220855A1 (en) 2003-10-13

Family

ID=28677597

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003220855A Abandoned AU2003220855A1 (en) 2002-04-01 2003-03-27 Medicinal antitumor composition

Country Status (3)

Country Link
AU (1) AU2003220855A1 (en)
TW (1) TW200305402A (en)
WO (1) WO2003082865A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108741A1 (en) * 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
JP5133071B2 (en) 2006-02-09 2013-01-30 第一三共株式会社 Anticancer pharmaceutical composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69726182T2 (en) * 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GROWTH PREVENTION OF TUMOR CELLS CONTAINING A PPAR-GAMMA AGONIST AND A MAP KINASE INHIBITOR
AU1507799A (en) * 1997-12-16 1999-07-05 Sankyo Company Limited Leukemia remedy
ATE466861T1 (en) * 1999-04-07 2010-05-15 Daiichi Sankyo Co Ltd AMINE DERIVATIVES
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
AU1303301A (en) * 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Body weight gain inhibitors

Also Published As

Publication number Publication date
WO2003082865A1 (en) 2003-10-09
TW200305402A (en) 2003-11-01

Similar Documents

Publication Publication Date Title
AU2003291103A1 (en) Pharmaceutical composition
AU2002313236A1 (en) Medicinal compositions
IL154761A0 (en) Improved paclitaxel-based antitumor formulation
AU2003285288A1 (en) Composition
AU2003250372A1 (en) Pharmaceutical composition
AU2002302147A1 (en) Pharmaceutical composition
AU2002950744A0 (en) Composition
AU2002258221A1 (en) Medicinal composition
AU2003235708A1 (en) Polytartrate composition
AU2003208411A1 (en) Anti-glycolytic composition
AU2003282722A1 (en) Therapeutic compositions
AU2003284460A1 (en) Medicinal composition
HK1081451A1 (en) Medicinal composition
AU2003280799A1 (en) Medicinal composition
AU2003216503A1 (en) Stable pharmaceutical compositions
AU2002354460A1 (en) Medicinal composition
AU2003220855A1 (en) Medicinal antitumor composition
AU2003280678A1 (en) Medicinal composition
HK1062274A1 (en) Medicinal composition
AU2003215935A1 (en) Anticancer composition
AUPR529701A0 (en) Pharmaceutical composition
AUPS188302A0 (en) Pharmaceutical composition
AU2003268772A1 (en) Oil-barrier composition
AU2002335161A1 (en) Medicinal composition
AU2002346223A1 (en) Medicinal compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase